Paid Clinical Trials Idaho
Discover 308 paid clinical trials in Idaho. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Deep Brain StimulationDeep Brain Stimulation (DBS) Retrospective Outcomes Study
Sponsor:
Boston Scientific Corporation
Location:
Code:
NCT03664609
Conditions
Parkinson Disease
Essential Tremor
Dystonia
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Deep Brain Stimulation
DiamydA Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Sponsor:
Diamyd Medical AB
Location:
Code:
NCT05018585
Conditions
Type 1 Diabetes Mellitus
Eligibility Criteria
Sex: All
Age: 12 - 28
Healthy Volunteers: Not accepted
Interventions
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
Colecalciferol 2000 IU
Placebo
Casdozokitug & Toripalimab, BevacizumabA Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Sponsor:
Coherus Biosciences, Inc.
Location:
Code:
NCT06679985
Conditions
Hepatocellular Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Casdozokitug
Toripalimab
Bevacizumab
REACTA Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Sponsor:
Prokidney
Location:
Code:
NCT05099770
Conditions
Type 2 Diabetes Mellitus
Chronic Kidney Diseases
Eligibility Criteria
Sex: All
Age: 30 - 70+
Healthy Volunteers: Not accepted
Interventions
Renal Autologous Cell Therapy (REACT)
Sham Comparator
DR-01A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
Sponsor:
Dren Bio
Location:
Code:
NCT06602232
Conditions
Alopecia Areata
Vitiligo
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
DR-01
Interested in new trials?
Get alerts for new trials in your area by subscribing now
BHV-7000A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
Sponsor:
Biohaven Therapeutics Ltd.
Location:
Code:
NCT06425159
Conditions
Generalized Epilepsy
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BHV-7000
Placebo
BarzolvolimabA Study of Barzolvolimab in Patients With Atopic Dermatitis
Sponsor:
Celldex Therapeutics
Location:
Code:
NCT06727552
Conditions
Atopic Dermatitis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Barzolvolimab
Matching placebo
Radiofrequency SUIProspective US Radiofrequency SUI Trial
Sponsor:
Viveve Inc.
Location:
Code:
NCT04720352
Conditions
Urinary Incontinence, Stress
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Active treatment
Sham
VAX-31A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
Sponsor:
Vaxcyte, Inc.
Location:
Code:
NCT06720038
Conditions
Pneumococcal Vaccines
Eligibility Criteria
Sex: All
Age: 42 - 70+
Healthy Volunteers: Accepted
Interventions
0.5 mL of the low dose VAX-31
0.5 mL of the mid dose VAX-31
0.5 mL of the high dose VAX-31
0.5 mL dose of PCV20
Rilvegostomig & PembrolizumabA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Sponsor:
AstraZeneca
Location:
Code:
NCT06692738
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Rilvegostomig
Pembrolizumab
Carboplatin
Paclitaxel
Nab-paclitaxel